These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1159815)

  • 1. Increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice.
    Campanile F; Houchens DP; Gaston M; Goldin A; Bonmassar E
    J Natl Cancer Inst; 1975 Jul; 55(1):207-9. PubMed ID: 1159815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell kinetics and immunoegenicity of lymphoma cells treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) in vivo.
    Silvestrini R; Testorelli C; Goldin A; Nicolin A
    Int J Cancer; 1977 May; 19(5):664-9. PubMed ID: 863544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
    Nicolin A; Franco P; Testorelli C; Goldin A
    Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines.
    Nicolin A; Bini A; Di Padova F; Goldin A
    J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
    Nicolin A; Fagnani R; Nicolotti G; Goldin A
    Experientia; 1976 Jun; 32(6):741-2. PubMed ID: 780128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
    Testorelli C; Franco P; Goldin A; Nicolin A
    Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
    Testorelli C; Archetti YL; Aresca P; Del Vecchio L
    Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of leukemic mice with viable drug-altered leukemic cells.
    Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A
    Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo.
    Nicolin A; Spreafico F; Bonmassar E; Goldin A
    J Natl Cancer Inst; 1976 Jan; 56(1):89-93. PubMed ID: 1255754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L1210/DTIC antigenic subline: studies at the clone level.
    Marelli O; Canti G; Franco P; Prandoni N; Ricci L; Nicolin A
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1401-5. PubMed ID: 2435557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives.
    Nardelli B; Contessa AR; Romani L; Sava G; Nisi C; Fioretti MC
    Cancer Immunol Immunother; 1984; 16(3):157-61. PubMed ID: 6561067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation resistance of drug-treated allogeneic mice against murine lymphomas--II. Studies with various tumor-host combinations.
    Bonmassar A; Rivosecchi-Merletti P; Barzi A; Goldin A; Bonmassar E
    Int J Immunopharmacol; 1981; 3(4):391-9. PubMed ID: 7333720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunity in mice challenged with L1210/DTIC clones.
    Canti G; Ricci L; Marelli O; Franco P; Nicolin A
    Cancer Immunol Immunother; 1987; 24(1):64-7. PubMed ID: 3545466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
    Fuji H; Mihich E; Pressman D
    J Natl Cancer Inst; 1979 Jun; 62(6):1503-10. PubMed ID: 286122
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacological alteration of the antigenic properties of experimental leukemias detected by lymphocyte transformation].
    Testorelli C; Missiroli A; Di Padova F; Nicolin A
    Boll Ist Sieroter Milan; 1976; 55(2):142-50. PubMed ID: 1023882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
    Guadagni F; Roselli M; Fuggetta MP; Perno CF; Goldin A; Giuliani A
    Chemioterapia; 1984 Dec; 3(6):358-64. PubMed ID: 6529777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.